EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tumor Microenvironment and Genes Affecting the Prognosis of Temozolomide-Treated Glioblastoma

Yena Jang iD, Wooyong Cheong iD, Gyurin Park iD, Yeongmin Kim iD, Junbeom Ha iD, Sangzin Ahn iD

Journal of Personalized Medicine · 20.01.2023 · 13 (2) · 188

DOI: 10.3390/jpm13020188 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 20.01.2023. Verfasst von Yena Jang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Inje University College of Medicine, Busan 47392, Republic of Korea. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Inje University, Inje University Research Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is the most frequent primary brain tumor in adults and has a poor prognosis due to its resistance to Temozolomide (TMZ). However, there is limited research regarding the tumor microenvironment and genes related to the prognosis of TMZ-treated GBM patients. This study aimed to identify putative transcriptomic biomarkers with predictive value in patients with GBM who were treated with TMZ. Publicly available datasets from The Cancer Genome Atlas and Gene Expression Omnibus were analyzed using CIBERSORTx and Weighted Gene Co-expression Network Analysis (WGCNA) to obtain types of highly expressed cell types and gene clusters. Differentially Expressed Genes analysis was performed and was intersected with the WGCNA results to obtain a candidate gene list. Cox proportional-hazard survival analysis was performed to acquire genes related to the prognosis of TMZ-treated GBM patients. Inflammatory microglial cells, dendritic cells, myeloid cells, and glioma stem cells were highly expressed in GBM tissue, and ACP7, EPPK1, PCDHA8, RHOD, DRC1, ZIC3, and PRLR were significantly associated with survival. While the listed genes have been previously reported to be related to glioblastoma or other types of cancer, ACP7 was identified as a novel gene related to the prognosis of GBM. These findings may have potential implications for developing a diagnostic tool to predict GBM resistance and optimize treatment decisions.

Schlagwörter

Stichwörter der Autor:innen

differentially expressed genesglioblastomapharmacogeneticsprecision medicinetemozolomidetranscriptometumor microenvironment

Autor:innen und Institutionen

  • Inje University College of Medicine, Busan 47392, Republic of Korea.
  • Department of Pharmacology and Pharmacogenomics Research Center, Inje University College of Medicine, Busan 47392, Republic of Korea.

ORCID-Profile: Yena Jang, Wooyong Cheong, Gyurin Park, Yeongmin Kim, Junbeom Ha, Sangzin Ahn

Förderung

  • Inje University
  • Inje University Research Grant

Zitieren

APA

Jang, Y., Cheong, W., Park, G., Kim, Y., Ha, J., & Ahn, S. (2023). Tumor Microenvironment and Genes Affecting the Prognosis of Temozolomide-Treated Glioblastoma. Journal of Personalized Medicine, 13(2), 188. https://doi.org/10.3390/jpm13020188

Vancouver

Jang Y, Cheong W, Park G, Kim Y, Ha J, Ahn S. Tumor Microenvironment and Genes Affecting the Prognosis of Temozolomide-Treated Glioblastoma. Journal of Personalized Medicine. 2023;13(2):188. doi:10.3390/jpm13020188

BibTeX
@article{Jang2023,
  author = {Jang, Yena and Cheong, Wooyong and Park, Gyurin and Kim, Yeongmin and Ha, Junbeom and Ahn, Sangzin},
  title = {Tumor Microenvironment and Genes Affecting the Prognosis of Temozolomide-Treated Glioblastoma},
  journal = {Journal of Personalized Medicine},
  year = {2023},
  volume = {13},
  number = {2},
  pages = {188},
  doi = {10.3390/jpm13020188}
}
Kostenlos starten →